Report Details:
15 Companies Covered
200 Pages
Market Highlights
The Global Pharmacogenomics Market size was valued at USD 4.77 Billion in 2024, and the market is projected to grow from USD 5.126 Billion in 2025 to USD 10.54 Billion by 2035, registering a CAGR of 7.4% during the forecast period 2025–2035.
Pharmacogenomics defines how genes can affect a person’s response to drugs. Pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. The growing biotech industry boosts the market growth. According to the Organization for Economic Co-operation and Development in 2017, biotech R&D in the business enterprise sector was 11.3%, and 9.4% of total business enterprise R&D, for U.S. and France respectively in 2014.
Moreover, in 2016, according to the BIOCOM AG, the total turnover for the Germany based biotech companies was USD 3.7 billion. Moreover, rising healthcare expenditures followed by increasing interest for customized drugs will drive the market growth. However, lack of awareness and consistency in pharmacogenomics products will restrain the market growth during the forecasted period.
Segmentation
The global pharmacogenomics market is segmented on the basis of technology, application, and end user.
On the basis of technology, the market is segmented into microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is sub-segmented into Sanger sequencing, pyrosequencing, next-generation sequencing, and others. On the basis of application, the market is segmented into oncology, cardiology, neurological disorders, and others.
The oncology segment, by technology, is sub-segmented into breast cancer, lung cancer, and others. On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others
Regional Analysis
America dominates the global pharmacogenomics market owing to a well-developed healthcare sector. Moreover, the presence of developed economies and rising number of patients suffering from cardiovascular diseases have boosted the growth of the market in America. In 2016, according to the Centres for Diseases Control and Prevention in the U.S., heart disease was the leading cause of death for both men and women
Europe is the second largest pharmacogenomics market, followed by the Asia Pacific region. Availability of funds for research and development along with government support within the region will drive the market growth during the forecasted period. Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China and presence of huge opportunities in the market drives the market.
On the other hand, the Middle East & Africa has the least share in the global pharmacogenomics market due to presence of poor economy and stringent government policies especially in Africa region. The majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Key Players
The key players for the global pharmacogenomics market are Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), and others.
